.Additionally,womenofchildbearing agemay haveacquired glaucomaearlyinchildhood (congenitalglaucoma,anteriorsegmentdysgenesis,or glaucomaaftercataractformation),orglaucomaresulting fromcoexistingconditionspresentingearlyinlife, uveitis ordiabetes.
CHANGES OF INTRAOCULAR PRESSURE IN PREGNANCY
IOPhasbeenproclaimedtofallduringpregnancy.Itis estimatedthatduringpregnancy,IOPdiminishesupto10%, withthisreductionbeingmarkedinthethirdquarter.The reductionsnotonlyoccurthroughoutthepregnancybutalso persistforseveralmonthspostpartum.Thisreductioninthe IOPisprimarilyattributedtothefluctuatinglevelsoftwo important hormones 茁-humanchorionicgonadotropin (B-hcg)andprogesterone. Inonestudyofpregnantwomen,themeanIOPoffirst trimesterpatientswasonaverage2mmHghigherthanthat ofthirdtrimesterpatients [3] .Theprobableriskofbirthdefects combinedwithpatients'apprehensionshasbeentempting ophthalmologiststoputanti-glaucomamedicationsonhold duringpregnancy.Infact,itmaysuggestthatglaucomabe stableduringpregnancyandthepatientsthereforebe off-treatmentduringpregnancy [4] [5] .Studiesofhealthywomen ascomparedtothosewithocularhypertensionshowedthat IOPdecreasedaspregnancy progresses,andresearch demonstratedastatisticallysignificantdropinpressurefrom thefirsttothethirdtrimester [4] [5] .Potentialmechanismsfor thisIOPreductionincludedgreateraqueousuveoscleral outflowfacilityduetohormonalchanges,hormoneinduced blockageofocularhypertensiveeffectof endogenous corticosteroids,decreasedepiscleralvenouspressurefrom reductionofvenouspressureintheupperlimbsandmild metabolicacidosisresultingfromgestation.Specifically, increasedlevelsofprogesteroneandrelaxinmaydecrease IOPandincreasethecoefficientoffacilityofaqueous outflowduringpregnancy [3] [4] [5] . However,theextenttowhichtheseIOPchangesshouldbe extrapolatedinpregnancywithpre-existingglaucomaisstill anenigma [6] .Theevolutionofglaucomaduringpregnancyis variabledespitethesocalledtheoreticalhormonalprotecting factor. Mostpatientsgenerallyremainstableduring pregnancyalthoughasmallpercentage(about10%)have increasedIOPorprogressionofthedisease [7] . [7] [8] . TreatmentGoals ThetargetIOPistheIOPrangeatwhich, intheophthalmologists'opinion,theestimatedrateof progressionisunlikelytoaffectthepatient'squalityoflife. Althoughrecommendedbymostexperts,thereisinsufficient evidencethatusingtargetIOPisassociatedwithbetter clinicaloutcomes.ThedeterminationofatargetIOPisbased uponconsiderationoftheamountofexistingglaucoma damage,therateofprogression,theIOPatwhichthedamage hasoccurred,thelifeexpectancyofthepatient,andother factorsincludingstatusofthefelloweyeandfamilyhistory ofsevereglaucoma [3] [4] [5] [6] [7] [8] . TheuseoftargetIOPinglaucomarequiresongoingcontinual re-evaluationandadjustments.Thebenefitsandadversitiesof escalatingtreatmenttoreachatargetIOPmusttendtoa equilibrium.Uncertaintiesregardingtheshort-andlong-term variationsofIOP,accuracyoftonometerreadings,patient's lifeexpectancy,adherencetotherapyand estimated progressionratesremainunresolved.Treatmentgoalsinclude IOP,visualfunctionandstructural(opticdisc,RNFL) outcomesandqualityoflife.Risksthattopicalandsystemic medicationsexposedtothefetusandneonatemustbe balancedagainsttheriskofvisionlossinthemother [3] [4] [5] [6] [7] [8] .
ANTI-GLAUCOMAMEDICATIONS Beta-blockers Oral 茁-blockersarecategorizedasclassC medicationsinpregnancy.Nospecificcategorizationis availablefortopical 茁-blockers.Topical 茁-adrenoceptor blockingdrugssuchastimolol,betaxolol,carteolol, levobunol,andmetipranol decreasetheproductionof aqueoushumourandsubsequentlylowertheIOP [9] [10] . Topical 茁-blockersareeffectiveIOP-loweringagents.All non-selective 茁-blockershavecomparableIOP-lowering efficacy.However,topicalandsystemic 茁-blockersare poorlyadditivewithrespecttoloweringIOP.Althoughsome 茁-blockershaveintrinsicsympathomimeticactivity(ISA)or 琢-blockingproperties,theirclinicalpropertiesaresimilarto thoseofothernon-selective 茁-antagonists.However,ISA mayreducerespiratoryandcardiovascularside-effects relatedto 茁-blockade.Timolol,andpossiblyallother 茁-blockers,haveminimalIOP-loweringefficacyduring sleep.Non-selectivetopical 茁-blockersarecontraindicatedin patientswithasthma,chronicobstructivepulmonarydisease (emphysemaandbronchitis),somecasesofcongestiveheart failure,bradycardia,andheartblock [9] [10] . Betaxololisrelativelysaferthananon-selective 茁-blockerin patientswithknownreactiveairwaydisease.However,the IOP-loweringefficacyofbetaxolol,despitebeingarelatively selective 茁-1-blocker,islessthanthatofnon-selective 茁-blockers.
Althoughophthalmologistsmaybereluctanttoprescribethis classofdrugstopregnantglaucomapatients,most obstetriciansareprettycomfortablewiththistypeoftherapy, becausetheydonothesitatetoprescribeoral 茁-blockersto controlhypertensionduringpregnancy.Systemicuseof 茁-adrenoceptorblockingdrugsneartermmayresultinfetal and neonatalbradycardia,arrhythmia,hypotensionand hypoglycaemia [11] [12] .Respiratorydistressandapnoeahavealso beenreportedfollowinginuteroexposure.Thedataonthe safetyofdiscontinuingtreatment24-48hbeforedeliveryare conflicting [9] [10] [11] [12] .Whenreported,neonatalsymptomsdueto 茁-blockadeareusuallymildandresolvewithin48h. [16] [17] [18] [19] . Latanoprostexposureinpregnancyhasnotbeenassociated withanincreasedriskofcongenitalmalformationsor spontaneousabortioninexposedinfants.Lowbirthweight wasfoundtobemorecommoninlatanoprost-exposedbabies thaninthe non-exposedcontrols,howevernoother differenceswereobservedbetweengroups [18] .Thereareno publisheddataregardingtheuseofbimatoprostortravoprost inpregnancy. Additionally,asystematicreviewdocumentedthatoralor vaginaluseofmisoprostolinpregnancyisassociatedwithan increasedriskofMoebiussyndromeandterminaltransverse limbdefects [20] ,thoughitisunclearwhethertheverylowdrug concentrationsusedinophthalmicprostaglandinformulations aresufficientenoughtoelicitthissideeffect.Whilesome 
pharmacologistsupholdthatlatanoprostandtravoprosthave insufficientactiveingredientstocauseadverseeffectsonthe foetus,othersbelievethattheuseofprostaglandinsis generallycontra-indicatedinpregnantwomen [17, 19] . [21] [22] [23] . BrinzolamideisclassifiedasacategoryCmedicationin pregnancy.Inanimalstudies,therewasastatisticallylower fetalbodyweightwiththeoralmedication(375timesthe humanophthalmicdose).However,noorganmalformations wereseenevenatthishighdose [24] .Dorzolamideisalso classifiedascategoryCmedication.Therewere malformationsofthevertebralbodiesinrabbitsexposedto dorzolamideduringpregnancy,suggestingthatbrinzolamide maybeabetteralternative.Nocontrolledreportsof brinzolamideordorzolamideexistinhumanpregnancy.As such,itmaybeusedduringpregnancywithcautionwhenthe possiblebenefittothemotheroutweighsthetheoreticalrisk tothefetus.Itisuncertainifthesemedicationsareexcreted inhumanmilk,andthustheirsafetyinbreastfeedingis unknown [24] [25] [26] . AcetazolamideisclassifiedasacategoryCmedication. Acetazolamidemayresultinpotentialmetabolic complicationstothe newbornorbreast-feedingchild. Systemichighdosecarbonicanhydraseinhibitorsinratscan resultinforelimbanomalieswhichmaysuggestthatthis medicationisteratogenic [27] [28] [29] .Onecasereportofneonatal sacrococcygealteratomawasreportedinapregnantwoman withmaternaloralacetazolamideuse [30] .In1989,anewborn infantdevelopedmetabolicacidosis,hypocalcaemia,and hypomagnesaemiabecausethemotherhadbeentreatedwith acetazolamide,pilocarpine,andtimololfor glaucoma throughoutherpregnancy [31] .Thebloodconcentrationof acetazolamideisrelatedtotheserumcarbondioxidelevel andchlorideionconcentration,whichareindicatorsof metabolicacidosisespeciallyifpatientshaverenal dysfunction [32] [33] .In2000,therewasanotherreportedcaseof thetransplacentalpassageofacetazolamidethatledto transientneonatalrenaltubularacidosisandlowbirthweight duringthetreatmentofmaternalglaucomawithoral acetazolamide [24] .Ontheotherhand,therewerenofetal adverseeffectsin12pregnantwomenwhousedoral acetazolamideforidiopathicintracranialhypertension management [34] .Alsoanothercasereportdemonstratedthat acetazolamideplasmalevelswerelowininfantsexposedto the medicationthroughbreast milk [25] .Therefore, acetazolamideisapprovedbytheAmericanAcademyof Pediatricsforuseduringnursing [8] . [36] .Additionally,bothnasolacrimalocclusion andeyelidsclosurecanincreaseeye-drugcontacttime resultinginhigherintraoculardrugconcentrations,andless systemicabsorption.Punctalpluggingcanreducetear drainageandimprovemeantearmeniscuslevelssuchthat systemicabsorptionofdrugislowered [36] [37] .However,there arenodirectstudiesonsystemicabsorptionofglaucoma medications withpunctalplugging.Nonetheless,these optionsshouldbediscussedwithwomenwhochooseto continuetopical IOP-loweringtherapyinandaround pregnancy. [28] .Aretrospective studyofArgonlasertrabeculoplastyreportedthat60%of laseredpatientshaduncontrolledIOPandrequiredglaucoma surgerywithintwoyearsfollowingALT [38] .However,given theshorttime-frameofpregnancy,trabeculoplastymaystill beconsideredinthesepatients. RoleofGlaucomaSurgery Ifawomanhasadvanced glaucomaandelevatedpressuresdespitetakingmultiple medications,seriousconsiderationshouldbegiventosurgery beforeconception.Afterconception,glaucomasurgerycould beconsidered duringpregnancyiftheglaucomais progressiveandanadequateIOPcannotbeobtaineddespite lasertrabeculoplastyandthe useofmaximumsafe medications.However,therearespecificrisksofglaucoma surgeryinpregnantpatients,includingtherisksoflocaland generalanesthesia,andtheneedforpost-operative medications.Additionally,glaucomafiltrationsurgeryin pregnantpatientsmaybeatrelativelyhigherriskoffailure becauseofyoung patientageandcontraindicated antimetaboliteusage [39] [40] . PubMed.gov searchusingtheterms"glaucoma", "pregnancy","IOPinpregnancy","anti-glaucomadrugsin pregnancy","ALTandSLTinpregnancy","trabeculectomy inpregnancy"and"choiceofanti-glaucomamedicationin pregnancy".Allavailablerelevantarticlespertainingtothis topicwerethenreviewed.
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